Momenta Pharmaceuticals to Webcast Presentation at the 38th Annual J.P. Morgan Healthcare Conference
December 24 2019 - 8:00AM
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that
Craig Wheeler, President and CEO, will present at the 38th Annual
J.P. Morgan Healthcare Conference. The presentation is scheduled
for Tuesday, January 14, 2020 at 3:00 p.m. PT (6:00 p.m. ET).
Following the presentation, management will
participate in a question and answer session at 3:30 p.m. PT (6:30
p.m. ET).
A webcast of the presentation and question and
answer session will be available live on the “Investors” section of
the company’s website located at www.momentapharma.com. A replay of
the presentation will be posted on the Momenta website
approximately one hour after the event.
About MomentaMomenta
Pharmaceuticals is a biotechnology company with a validated
innovative scientific platform focused on discovering and
developing novel therapeutics to treat rare, immune-mediated
diseases and advancing its late stage biosimilar portfolio. The
company is headquartered in Cambridge, MA.
To learn more about Momenta, please visit
www.momentapharma.com, which does not form a part of this press
release.
Momenta’s logo, trademarks, and service marks
are the property of Momenta Pharmaceuticals, Inc. All other trade
names, trademarks, or service marks are property of their
respective owners.
Forward-Looking Statements
Statements in this press release regarding management's future
expectations, beliefs, intentions, goals, strategies, plans or
prospects, are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including but not
limited to statements about the use efficacy, safety, tolerability,
convenience and commercial potential of our product candidates.
Forward-looking statements may be identified by words such as
"believe," "continue," “plan to”, "potential," "will," and other
similar words or expressions, or the negative of these words or
similar words or expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other important
factors, including the risk of the unpredictable nature of early
stage development efforts for our product candidates; safety,
efficacy or tolerability problems with our product candidates;
unexpected adverse clinical trial results; and those referred to
under the section "Risk Factors" in the Company's Quarterly Report
on Form 10-Q for the quarter ended September 30, 2019 filed with
the Securities and Exchange Commission, as well as other documents
that may be filed by the Company from time to time with the
Securities and Exchange Commission. As a result of such risks,
uncertainties and factors, the Company's actual results may differ
materially from any future results, performance or achievements
discussed in or implied by the forward-looking statements contained
herein. The Company is providing the information in this press
release as of this date and assumes no obligations to update the
information included in this press release or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contact: Patty Eisenhaur Momenta
Pharmaceuticals1-617-395-5189IR@momentapharma.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024